Clinical Trial Update: Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN [Phase 1, Phase 2]

View source ↗

Summary

An ongoing Phase 1/2 trial of IMGN632 for untreated and relapsed/refractory Blastic plasmacytoid dendritic cell neoplasm. The study is currently active but not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blastic Plasmacytoid Dendritic Cell Neoplasm
• Myeloproliferative Neoplasm

Drugs mentioned

• IMGN632

Snippet

Sponsor: AbbVie | Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING